Get the Stockscreener App
1.80
11.71%
-0.25
Phio Pharmaceuticals Corp stock is traded at $1.80, with a volume of 156.36M.
It is down -11.71% in the last 24 hours and down -24.27% over the past month.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
See More
Previous Close:
$2.05
Open:
$3.47
24h Volume:
156.36M
Relative Volume:
64.03
Market Cap:
$10.16M
Revenue:
-
Net Income/Loss:
$-11.66M
P/E Ratio:
-0.2207
EPS:
-8.156
Net Cash Flow:
$-11.09M
1W Performance:
-16.29%
1M Performance:
-24.27%
6M Performance:
-7.66%
1Y Performance:
-41.99%
1-Day Range:
$1.7201
$4.1899
1-Week Range:
$1.845
$4.1899
52-Week Range:
$0.9657
$9.79
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Name
Phio Pharmaceuticals Corp
Sector
Industry
Phone
(508) 767-3861
Address
411 SWEDELAND ROAD, KING OF PRUSSIA, MA
Compare PHIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
1.775 | 11.74M | 0 | -11.66M | -11.09M | -8.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.41 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.28 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.39 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
821.96 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.19 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Resumed | H.C. Wainwright | Buy |
| Aug-05-20 | Initiated | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Stock (PHIO) Latest News
Why Is Phio Pharmaceuticals Stock Up 75% Today? - TipRanks
Phio Pharmaceuticals Reports Positive Phase 1b Trial Results - TipRanks
Phio Pharmaceuticals Corp Announces Positive Results in Skin Cancer Trial - TradingView
Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial - Newsfile
Is Phio Pharmaceuticals Corp. stock attractive for retirement portfolios2025 Geopolitical Influence & Expert-Curated Trade Recommendations - newser.com
How Phio Pharmaceuticals Corp. (44R1) stock reacts to fiscal policiesQuarterly Trade Summary & Growth Focused Entry Point Reports - newser.com
Best data tools to analyze Phio Pharmaceuticals Corp. stockLayoff News & Expert Approved Momentum Trade Ideas - newser.com
Phio Pharmaceuticals Corp. stock retracement – recovery analysisMarket Risk Report & Real-Time Volume Trigger Notifications - newser.com
How Phio Pharmaceuticals Corp. (44R1) stock reacts to new regulations2025 Price Momentum & Risk Managed Trade Strategies - newser.com
Can Phio Pharmaceuticals Corp. hit a new high this month2025 Valuation Update & Fast Exit Strategy with Risk Control - newser.com
Is Phio Pharmaceuticals Corp. stock in correction or buying zone2025 Investor Takeaways & Expert Approved Momentum Ideas - newser.com
Developing predictive dashboards with Phio Pharmaceuticals Corp. dataWeekly Trade Recap & AI Based Buy/Sell Signal Reports - newser.com
Can Phio Pharmaceuticals Corp. rally from current levelsQuarterly Investment Review & Safe Entry Trade Reports - newser.com
What to do if you’re stuck in Phio Pharmaceuticals Corp.Quarterly Profit Report & Real-Time Buy Signal Notifications - newser.com
Top chart patterns to watch in Phio Pharmaceuticals Corp.Rate Cut & Technical Pattern Recognition Alerts - newser.com
Phio Pharmaceuticals appoints David Deming as lead independent director By Investing.com - Investing.com Australia
How Phio Pharmaceuticals Corp. stock benefits from tech adoptionQuarterly Portfolio Report & Precise Entry and Exit Recommendations - newser.com
What drives Phio Pharmaceuticals Corp 44R1 stock priceAnalyst Downgrades & Access Insider-Level Stock Analysis - earlytimes.in
Phio Pharmaceuticals Corp. (PHIO) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Phio Pharmaceuticals Appoints New Lead Independent Director - TipRanks
Phio Pharmaceuticals Corp. Announces Appointment of David H. Deming as Lead Independent Director - MarketScreener
[8-K] Phio Pharmaceuticals Corp. Reports Material Event | PHIO SEC FilingForm 8-K - Stock Titan
Phio Pharmaceuticals appoints David Deming as lead independent director - Investing.com
Phio Pharmaceuticals Announces Board Resignation - TradingView
Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director - Newsfile
Phio (NASDAQ: PHIO) names David H. Deming lead independent director, with over 30 years - Stock Titan
Is Phio Pharmaceuticals Corp. stock supported by strong fundamentalsPortfolio Risk Summary & Free Growth Oriented Trading Recommendations - newser.com
Will Phio Pharmaceuticals Corp. stock outperform tech sector in 2025GDP Growth & Pattern Based Trade Signal System - newser.com
Using economic indicators to assess Phio Pharmaceuticals Corp. potential2025 Top Decliners & Fast Gain Swing Trade Alerts - newser.com
Will Phio Pharmaceuticals Corp. stock rally after Fed decisionsShort Setup & Low Drawdown Momentum Ideas - newser.com
Is Phio Pharmaceuticals Corp. (44R1) stock included in top ETFsWeekly Loss Report & Weekly Watchlist of Top Performers - newser.com
How currency fluctuations impact Phio Pharmaceuticals Corp. stockDip Buying & Stepwise Trade Signal Implementation - newser.com
Analyzing Phio Pharmaceuticals Corp. with multi timeframe chartsPortfolio Profit Report & Verified Swing Trading Watchlists - newser.com
Phio Pharmaceuticals Corp Stock (PHIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.29%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):